New scientific article shows that Patrys' PAT-SC1 safe, well-tolerated in gastric cancer patients

Patrys Limited (ASX: PAB), a clinical stage biotechnology company is pleased to announce the publication of a new scientific article regarding its product PAT-SC1 in the Oncology Reports journal. The article is currently available online and will be included in a future print edition of the journal.

This newly published article is on a study, conducted between 1997 and 2001, that investigated the effect of PAT-SC1 in patients with gastric cancer who had also undergone gastric resection surgery.

It has been previously shown that a single 20mg dose of PAT-SC1 administered before surgery induced cell killing in human primary gastric tumours, leading to tumour cell regression in over half of PAT-SC1-treated patients. The newly published data are related to the 10 year follow up study of the patients that participated in the trial.  Survival at 10 years is significantly higher for PAT-SC1 treated patients as compared to an historical control group of patients that underwent a gastric resection but were not treated with PAT-SC1. Furthermore, PAT-SC1 was well tolerated in all treated patients with no significant side-effects being observed.

This work is the result of a collaboration between the Institute of Pathology, University of Würzburg, Department of Medicine, University of Würzburg, Department of Surgery, University of Kiel, and Patrys.

The senior author of this paper Dr. Stephanie Brändlein commented: “Even after treatment and radical surgery in gastric cancer patients, some cancer cells persist and disseminate throughout the body causing metastasis and recurrences of tumours.”

“PAT-SC1 effectively induces killing of these cells through a specific antigen binding mechanism thus improving the patient’s prognosis. These results are very exciting as this is the first time that a monoclonal IgM antibody like PAT-SC1 has been administered to such patients and the first time that an antibody treatment has resulted in a significant survival benefit.”

These findings further indicate that PAT-SC1 has a strong potential to be used as an additive therapeutic agent in the treatment of patients with gastric cancers.  Given in combination with radical standard surgery, PAT-SC1 could induce killing of tumour cells in various stages of growth, resulting in an improved survival of these patients.